Panel Nixes Tolvaptan On Weak Efficacy Data And Liver Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
Small, unclear drug effect and hepatotoxicity take down Otsuka’s tolvaptan kidney disease indication at Cardiovascular and Renal Drugs Advisory Committee review.
You may also be interested in...
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
The latest US drug development news and highlights from our Performance Tracker.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.